Hainan Shuangcheng Pharmaceut (002693) - Net Assets
Based on the latest financial reports, Hainan Shuangcheng Pharmaceut (002693) has net assets worth CN¥419.93 Million CNY (≈ $61.45 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥816.14 Million ≈ $119.43 Million USD) and total liabilities (CN¥396.21 Million ≈ $57.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002693 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥419.93 Million |
| % of Total Assets | 51.45% |
| Annual Growth Rate | 11.11% |
| 5-Year Change | -25.8% |
| 10-Year Change | -23.97% |
| Growth Volatility | 71.2 |
Hainan Shuangcheng Pharmaceut - Net Assets Trend (2009–2025)
This chart illustrates how Hainan Shuangcheng Pharmaceut's net assets have evolved over time, based on quarterly financial data. See how many days can Hainan Shuangcheng Pharmaceut fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Hainan Shuangcheng Pharmaceut (2009–2025)
The table below shows the annual net assets of Hainan Shuangcheng Pharmaceut from 2009 to 2025. For live valuation and market cap data, see 002693 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥420.53 Million ≈ $61.54 Million |
+2.17% |
| 2024-12-31 | CN¥411.61 Million ≈ $60.23 Million |
-20.49% |
| 2023-12-31 | CN¥517.65 Million ≈ $75.75 Million |
-10.90% |
| 2022-12-31 | CN¥580.94 Million ≈ $85.01 Million |
+2.50% |
| 2021-12-31 | CN¥566.75 Million ≈ $82.93 Million |
-5.27% |
| 2020-12-31 | CN¥598.31 Million ≈ $87.55 Million |
-11.79% |
| 2019-12-31 | CN¥678.26 Million ≈ $99.25 Million |
+1.28% |
| 2018-12-31 | CN¥669.69 Million ≈ $98.00 Million |
-12.08% |
| 2017-12-31 | CN¥761.71 Million ≈ $111.46 Million |
+37.71% |
| 2016-12-31 | CN¥553.13 Million ≈ $80.94 Million |
-40.37% |
| 2015-12-31 | CN¥927.61 Million ≈ $135.74 Million |
+3.81% |
| 2014-12-31 | CN¥893.55 Million ≈ $130.75 Million |
+2.63% |
| 2013-12-31 | CN¥870.62 Million ≈ $127.40 Million |
+2.93% |
| 2012-12-31 | CN¥845.85 Million ≈ $123.77 Million |
+270.61% |
| 2011-12-31 | CN¥228.23 Million ≈ $33.40 Million |
+44.62% |
| 2010-12-31 | CN¥157.82 Million ≈ $23.09 Million |
+102.47% |
| 2009-12-31 | CN¥77.95 Million ≈ $11.41 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hainan Shuangcheng Pharmaceut's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 717.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥818.68 Million | 198.49% |
| Total Equity | CN¥412.46 Million | 100.00% |
Hainan Shuangcheng Pharmaceut Competitors by Market Cap
The table below lists competitors of Hainan Shuangcheng Pharmaceut ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PDS Limited
NSE:PDSL
|
$529.57 Million |
|
Beijing Career International Co Ltd
SHE:300662
|
$529.61 Million |
|
Indigo Paints Limited
NSE:INDIGOPNTS
|
$529.67 Million |
|
Duratec Ltd
AU:DUR
|
$529.73 Million |
|
Serve Robotics Inc. Common Stock
NASDAQ:SERV
|
$529.07 Million |
|
Shenzhen Asiantime International Construction Co Ltd
SHE:002811
|
$529.07 Million |
|
Viyash Scientific Limited
NSE:SEQUENT
|
$529.07 Million |
|
Gazit Globe Ltd
TA:GZT
|
$528.92 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hainan Shuangcheng Pharmaceut's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 393,409,970 to 412,457,417, a change of 19,047,447 (4.8%).
- Net income of 19,043,164 contributed positively to equity growth.
- Dividend payments of 7,267,901 reduced retained earnings.
- Other comprehensive income decreased equity by 86,316,817.
- Other factors increased equity by 93,589,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥19.04 Million | +4.62% |
| Dividends Paid | CN¥7.27 Million | -1.76% |
| Other Comprehensive Income | CN¥-86.32 Million | -20.93% |
| Other Changes | CN¥93.59 Million | +22.69% |
| Total Change | CN¥- | 4.84% |
Book Value vs Market Value Analysis
This analysis compares Hainan Shuangcheng Pharmaceut's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.77x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 34.16x to 8.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | CN¥0.26 | CN¥8.72 | x |
| 2010-12-31 | CN¥0.52 | CN¥8.72 | x |
| 2011-12-31 | CN¥0.75 | CN¥8.72 | x |
| 2012-12-31 | CN¥2.32 | CN¥8.72 | x |
| 2013-12-31 | CN¥2.17 | CN¥8.72 | x |
| 2014-12-31 | CN¥2.21 | CN¥8.72 | x |
| 2015-12-31 | CN¥2.29 | CN¥8.72 | x |
| 2016-12-31 | CN¥1.37 | CN¥8.72 | x |
| 2017-12-31 | CN¥1.87 | CN¥8.72 | x |
| 2018-12-31 | CN¥1.28 | CN¥8.72 | x |
| 2019-12-31 | CN¥1.33 | CN¥8.72 | x |
| 2020-12-31 | CN¥1.20 | CN¥8.72 | x |
| 2021-12-31 | CN¥1.19 | CN¥8.72 | x |
| 2022-12-31 | CN¥1.14 | CN¥8.72 | x |
| 2023-12-31 | CN¥1.12 | CN¥8.72 | x |
| 2024-12-31 | CN¥0.95 | CN¥8.72 | x |
| 2025-12-31 | CN¥0.99 | CN¥8.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hainan Shuangcheng Pharmaceut utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.88%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 2.00x
- Recent ROE (4.62%) is above the historical average (1.39%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 41.19% | 36.41% | 0.90x | 1.26x | CN¥24.31 Million |
| 2010 | 40.70% | 56.90% | 0.45x | 1.60x | CN¥48.45 Million |
| 2011 | 30.85% | 52.74% | 0.54x | 1.09x | CN¥47.59 Million |
| 2012 | 8.04% | 52.44% | 0.15x | 1.05x | CN¥-16.59 Million |
| 2013 | 7.67% | 44.63% | 0.16x | 1.05x | CN¥-20.29 Million |
| 2014 | 6.80% | 37.71% | 0.17x | 1.06x | CN¥-28.58 Million |
| 2015 | 5.68% | 22.81% | 0.15x | 1.67x | CN¥-40.08 Million |
| 2016 | -70.22% | -267.62% | 0.12x | 2.11x | CN¥-443.72 Million |
| 2017 | 1.07% | 2.56% | 0.18x | 2.33x | CN¥-52.82 Million |
| 2018 | -13.30% | -20.60% | 0.30x | 2.15x | CN¥-121.66 Million |
| 2019 | 4.51% | 7.11% | 0.36x | 1.74x | CN¥-29.97 Million |
| 2020 | -10.82% | -19.79% | 0.30x | 1.84x | CN¥-102.62 Million |
| 2021 | -4.22% | -6.35% | 0.37x | 1.77x | CN¥-68.51 Million |
| 2022 | 1.75% | 3.28% | 0.30x | 1.77x | CN¥-42.34 Million |
| 2023 | -10.76% | -21.51% | 0.29x | 1.70x | CN¥-97.89 Million |
| 2024 | -19.90% | -44.95% | 0.22x | 1.99x | CN¥-117.65 Million |
| 2025 | 4.62% | 6.88% | 0.34x | 2.00x | CN¥-22.20 Million |
Industry Comparison
This section compares Hainan Shuangcheng Pharmaceut's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,988,841
- Average return on equity (ROE) among peers: 4.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hainan Shuangcheng Pharmaceut (002693) | CN¥419.93 Million | 41.19% | 0.94x | $529.15 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $565.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $654.09 Million | 2.17% | 0.78x | $359.03 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $0.00 | 0.00% | 0.00x | $4.30 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $973.90 Million | 0.17% | 0.60x | $2.52 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.41 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $3.19 Billion | 14.61% | 0.55x | $12.64 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $715.72 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $307.22 Million | 6.68% | 0.79x | $319.94 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.55 Billion | 4.67% | 3.16x | $916.75 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $25.04 Billion | 7.11% | 0.16x | $3.00 Billion |
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more